In our ongoing look at the EMD Serono Specialty Digest, we look today at the benefit management trends. (Specialty Digest) More plans are planning to add cost share tiers and coinsurance for drug benefit specialty compounds and they are planning for more cost-sharing in the medical benefit as well. A minority of plans either do or are looking at allowing 90 day supplies. Prior authorization has become near universal and the use of electronic portals for prior authorization is gaining steam. Plans are also taking steps to ensure use of preferred products. The group within a plan that is responsible for utilization management differs and often depends on whether it is a drug or medical benefit, but plans say they recognize the need for more consistent and singular management of these compounds. PBMs are making some headway in managing specialty drugs for their clients with about a quarter of the plans using them in 2012. In regard to medical benefit drugs, plans are trying to get basic NDC claims data, get the patient to use a preferred site of care, be able to do claims repricing with a fee schedule and contract for rebates. There are over 20 categories of specialty drugs with alternatives, so that there can be a preferred medicine. Almost all plans have at least one category with a preferred product and the trend is to add more. To ensure use of preferred products, plans are blocking the use of manufacture coupons on non-preferred ones. In terms of provider reimbursement, while AWP methodologies are most common, provider capitation in some categories is growing. Commercial plans are reimbursing providers at a higher rate than Medicare and Medicaid plans do. Plans are also considering having preferred infusion networks and leveraging 340B pricing.
✅ Subscribe via Email
About this Blog
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
Masking Kids Was Futile and Damaging
February 7, 2025
Masking Kids Was Futile and Damaging
The evidence clearly shows that masking children made no difference in CV-19 infection rates.
Commentary
The First Trump Era Jobs Report
February 7, 2025
The First Trump Era Jobs Report
Incorporating major population and job revisions, the report on January jobs is about as expected.
Commentary
No Need for More CV-19 Vax Doses
February 5, 2025
No Need for More CV-19 Vax Doses
Studies continue to show essentially no benefit from additional doses of CV-19 vax.